In the GBM AGILE platform trial, regorafenib did not improve overall survival vs control (temozolomide plus radiotherapy, or lomustine) in newly diagnosed unmethylated or recurrent glioblastoma (median HR 1.07 overall), stopped for limited efficacy, and increased toxicity.
RCT
Wen et al. Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial